ReviewTherapeutic advances in cardiovascular disease2016
The emerging role of endothelin-1 in the pathogenesis of pre-eclampsia.
Review in Therapeutic advances in cardiovascular disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 1 synthesis or guideline pooled it, 125 citations in OpenAlex.
- Selective serotonin reuptake inhibitors and preeclampsia: A quality assessment and meta-analysis.Pregnancy hypertension · 2022Pooled it
- Prenatal aspirin use is associated with preserved vascular endothelial function measured after pregnancy in women with a history of preeclampsia.Pregnancy hypertension · 2026Article
- Endothelial cells exposed to preeclamptic placental macrophages show increased oxidative stress and impaired angiogenesis in vitro.Pregnancy hypertension · 2026Article
- The endothelin-1/TLR4/NF-κB/NLRP3 inflammasome axis in preeclampsia: a review of a pathological feed-forward loop and therapeutic frontier.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Fetal cardiac remodeling in second trimester in pregnancies with pre-eclampsia and/or fetal growth restriction: deep-learning-based approach using population-wide data.Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology · 2026Article
- Eplerenone lowers maternal blood pressure in a model of leptin-induced preeclampsia, but decreases fetal growth when administered mid-, but not late-, gestation.American journal of physiology. Heart and circulatory physiology · 2026Article
- Cardiovascular biomarkers and preeclampsia: A narrative review.European journal of clinical investigation · 2026Review
- An appraisal of the role of asymmetric dimethylarginine on endothelial impairment in preeclampsia comorbid with HIV infection.Frontiers in medicine · 2026Review
- The multifactorial role of HDAC9 at the maternal-fetal interface in the pathogenesis of preeclampsia.Clinical science (London, England : 1979) · 2025Review
- Targeting IL6-Edn1-FoxO1 axis enables lung growth in mechanically ventilated newborn mice.The European respiratory journal · 2025Article
- Article
- The human placenta and its role in reproductive outcomes revisited.Physiological reviews · 2025Review
- Low-Molecular-Weight Heparin in Preeclampsia: Effects on Biomarkers and Prevention: A Narrative Review.Biomedicines · 2025Review
- Increased circulating Endothelin-1 is a risk factor for ECMO use and mortality in neonates with congenital diaphragmatic hernia: a prospective observational study.Respiratory research · 2025Observational
- Multiscale homogenized constrained mixture model of the bio-chemo-mechanics of soft tissue growth and remodeling.Biomechanics and modeling in mechanobiology · 2024Article
- Preeclampsia: Etiology, Pathophysiology, Risk Factors, Impact and Prevention: A Narrative Review.Iranian journal of public health · 2024Review
- IL-33 Signaling Inhibition Leads to a Preeclampsia-Like Phenotype in Pregnant Rats.American journal of reproductive immunology (New York, N.Y. : 1989) · 2024Article
- Pregnancy in Glomerular Disease: From Risk Identification to Counseling and Management.Journal of clinical medicine · 2024Review
- Review
- Hypertension in Cardio-Oncology Clinic: an update on etiology, assessment, and management.Cardio-oncology (London, England) · 2023Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pre-eclampsia (PE) is the most frequently encountered medical complication during pregnancy. It is characterized by a rise in systemic vascular resistance with a relatively low cardiac output and hypovolemia, combined with severe proteinuria. Despite the hypovolemia, renin-angiotensin system (RAS) activity is suppressed and aldosterone levels are decreased to the same degree as renin. This suggests that the RAS is not the cause of the hypertension in PE, but rather that its suppression is the consequence of the rise in blood pressure. Abnormal placentation early in pregnancy is widely assumed to be an important initial event in the onset of PE. Eventually, this results in the release of anti-angiogenic factors [in particular, soluble Fms-like tyrosine kinase-1 (sFlt-1)] and cytokines, leading to generalized vascular dysfunction. Elevated sFlt-1 levels bind and inactivate vascular endothelial growth factor (VEGF). Of interest, VEGF inhibition with drugs like sunitinib, applied in cancer patients, results in a PE-like syndrome, characterized by hypertension, proteinuria and renal toxicity. Both in cancer patients treated with sunitinib and in pregnant women with PE, significant rises in endothelin-1 occur. Multiple regression analysis revealed that endothelin-1 is an independent determinant of the hypertension and proteinuria in PE, and additionally a renin suppressor. Moreover, studies in animal models representative of PE, have shown that endothelin receptor blockers prevent the development of this disease. Similarly, endothelin receptor blockers are protective during sunitinib treatment. Taken together, activation of the endothelin system emerges as an important pathway causing the clinical manifestations of PE. This paper critically addresses this concept, taking into consideration both clinical and preclinical data, and simultaneously discusses the therapeutic consequences of this observation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.